A systematic review looked at 32 clinical guidelines for osteoporosis used in China. All of them were written for Chinese adults with primary osteoporosis. The review did not test any medicine or treatment. It compared what the guidelines say.
The guidelines mostly agreed on the basics. They shared the same definition of osteoporosis, the same diagnostic criteria, and the same general prevention strategies. They also agreed that treatment should include both medicines and non-medicine approaches.
But they disagreed on specific treatment recommendations. The differences often followed the writer's specialty, such as orthopaedics, endocrinology, or geriatrics. Only some guidelines mentioned fracture liaison services, which help connect patients to follow-up care after a broken bone. Only some included health economic considerations, meaning cost and value for the health system.
The review did not report safety data, funding sources, or conflicts of interest. It also did not report its own limitations. The main point is that guideline consistency was studied, not whether any treatment works. Readers should not take this as evidence for or against a specific osteoporosis drug. If you have osteoporosis, talk with your doctor about which guidance applies to you.
Common questions
What did this review of osteoporosis guidelines actually look at?
It compared 32 clinical guidelines for osteoporosis used in China. All were for Chinese adults with primary osteoporosis. The review looked at where the guidelines agreed and where they differed. It did not test any treatment or measure patient outcomes. It is a comparison of written recommendations, not a clinical trial.
Where do the Chinese osteoporosis guidelines disagree?
They mostly agree on the definition of osteoporosis, diagnostic criteria, prevention strategies, and including both pharmacological and non-pharmacological treatments. They differ on specific treatment recommendations, often based on the writer's clinical focus, such as orthopaedics, endocrinology, or geriatrics. Some guidelines also left out fracture liaison services and health economic considerations.
Does this review say which osteoporosis treatment is best?
No. The review evaluates the consistency of guidelines, not the clinical efficacy of treatments. It cannot tell you which medicine works better or is safer. If you are deciding on treatment, ask your doctor, who can consider your personal health situation and the most current guidance.
Why does it matter if guidelines are inconsistent?
When guidelines differ, the care a person receives may depend on which specialist they see. The review authors say this highlights a need for more coherent, evidence-based national guidelines that also include health economic evidence. That could help make care more consistent across China.
